Serum-free media drive the upgrading of vaccine and recombinant protein processes.

Trends in Serum Replacement in Upstream Biopharmaceutical Processes

The production of vaccines and recombinant protein drugs places extremely high demands on the stability of culture media. For a long time, fetal bovine serum (FBS) has been widely used as a culture supplement, but fluctuations in its supply, price variability, and the potential risks of prion and viral contamination have prompted the industry to gradually shift toward serum-free media. In large-scale bioreactor culture, serum-free media help simplify downstream purification steps, reduce interference from serum proteins with target products, and simultaneously decrease batch-to-batch variability and improve process consistency.

From a regulatory perspective, the use of animal-derived components is strictly restricted, especially in the fields of human vaccines and therapeutic proteins. Because serum-free media eliminate serum components, they are generally more readily able to meet relevant regulatory requirements for raw material traceability and safety. For manufacturers, adopting serum-free media also helps reduce supply chain risks and improve the stability of production planning. Therefore, an increasing number of newly built production lines are considering the use of serum-free culture systems from the initial design stage.

Process Adaptation of Serum-Free Media in Vaccine Production

Different cell substrates used for vaccine production have different nutritional requirements, such as Vero cells, MDCK cells, CHO cells, HEK293 cells, and others. Serum-free media need to be formulation-optimized for each cell type to support high-density cell growth and virus propagation. Generally, this is achieved by adjusting amino acids, vitamins, lipids, growth factors, and buffer salt concentrations to meet cellular metabolic demands. For adherent cells, it may also be necessary to add animal-origin-free recombinant adhesion proteins or adopt microcarrier culture.

In viral vaccine production, another advantage of serum-free media is the reduction of the effects of neutralizing antibodies or inhibitory factors that may be present in serum on virus amplification. This helps improve the consistency of viral titers and the predictability of vaccine yields. Of course, media optimization needs to be coordinated with parameters such as virus inoculation, culture conditions, and harvest timing, and cannot be viewed in isolation.

Media Strategies in Recombinant Protein Expression

For commonly used expression systems such as CHO cells, serum-free media are highly commercialized, and many formulations have undergone long-term optimization to support cells reaching higher densities in suspension culture. Such media are typically chemically defined or chemically defined media, free of animal-derived components, facilitating metabolic analysis and process scale-up. During use, attention needs to be paid to quality attributes such as cell growth rate, protein expression level, glycosylation modification, and product charge heterogeneity.

During the scale-up stage, batch-to-batch stability, solubility, osmolality, and trace element content of the media all require strict monitoring. Some companies adopt platform serum-free media and then optimize feeding strategies based on specific clones. Through rational design of feed media and fed-batch schemes, the culture period can be extended and recombinant protein yields increased. However, care must be taken to avoid excessively pursuing high density at the expense of cell viability and product quality.

Overall, serum-free media have become important foundational materials in vaccine and recombinant protein production processes. Their promotion and application not only align with regulatory trends but also help companies achieve more stable and more efficient production goals.